文献速递间质性肺疾病呼吸危重症与机械通气

肺移植后肺纤维化合并肺气肿的临床特征与结局

Clinical Features and Outcomes of Combined Pulmonary Fibrosis and Emphysema After Lung Transplantation.
PubMed 文献 · Chest · 2021-06-26

单中心回顾性队列研究纳入2011至2016年肺移植患者,比较肺纤维化合并肺气肿(CPFE)与特发性肺纤维化(IPF)的临床特征与移植后结局。CPFE占IPF患者的16%,其移植后原发性移植物功能障碍3级、急性细胞排斥反应≥A2及慢性移植物功能障碍风险显著高于IPF,但5年生存率无显著差异。

要点

  • CPFE患者肺移植后PGD 3级、ACR≥A2及CLAD风险显著高于IPF患者。
  • CPFE与IPF两组肺移植后5年生存率无显著差异。
  • CPFE患者中重度肺动脉高压比例较高,占59%。

核心结论

  • 肺移植后CPFE患者较IPF患者更易发生PGD、ACR和CLAD,但两组生存无显著差异。

研究设计与样本

  • CPFE定义为高分辨率CT上上肺野肺气肿≥10%合并纤维化。

主要发现

  • 172例IPF患者中27例(16%)符合CPFE标准。
  • 27例CPFE患者中16例(59%)存在重度肺动脉高压。

临床怎么用

  • 肺移植前识别CPFE有助于预判术后PGD、ACR和CLAD风险升高。
  • CPFE患者肺移植后需加强移植物功能监测与排斥反应管理。

局限性

  • 单中心回顾性研究,样本量有限,CPFE组仅27例。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Combined pulmonary fibrosis and emphysema (CPFE) is recognized as a characteristic syndrome of smoking-related interstitial lung disease that has a worse prognosis than idiopathic pulmonary fibrosis (IPF). However, outcomes after lung transplantation for CPFE have not been reported. The aim of this study is to describe the clinical features and outcomes of CPFE after lung transplantation. RESEARCH QUESTION: What are the clinical features and outcomes of CPFE after lung transplantation? STUDY DESIGN AND METHODS: This is a single-center retrospective cohort study of patients with CPFE and IPF who underwent lung transplantation at our center between January 2011 and December 2016. We defined CPFE as ≥10% emphysema in the upper lung fields combined with fibrosis on high-resolution CT scan. We characterized the clinical features of patients with CPFE and compared their outcomes after lung transplantation with those with IPF. RESULTS: Twenty-seven of 172 (16%) patients with IPF met criteria for CPFE. Severe pulmonary hypertension was present in 16 of 27 (59%) patients with CPFE. On logistic regression analysis, CPFE was significantly associated with primary graft dysfunction (PGD) grade 3 (OR, 3.14; 95% CI, 1.18-8.37; P = .02). On competing risk regression analysis, CPFE was associated with acute cellular rejection (ACR) grade ≥ A2, and chronic lung allograft dysfunction (CLAD) (hazard ratio [HR], 1.89; 95% CI, 1.10-3.25; P = .02; HR, 1.96; 95% CI, 1.02-3.77; P = .04, respectively). Five-year survival was 79.0% for the CPFE group and 75.4% for the IPF group (log-rank P = .684). INTERPRETATION: After transplantation, patients with CPFE were more likely to develop PGD, ACR, and CLAD compared with those with IPF. However, survival was not significantly different between the two groups.

来源:Chest,查看原文。版权归原作者所有。

引用

  1. Takahashi T, Terada Y, Pasque MK, et al. Clinical Features and Outcomes of Combined Pulmonary Fibrosis and Emphysema After Lung Transplantation. Chest. 2021. PMID: 34186034. doi:10.1016/j.chest.2021.06.036

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。